Asset
CONIVAPTAN HYDROCHLORIDE
Cumberland Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01370148 | phase1 | completed | 2011-04-01 | 2014-02-01 | Cumberland Pharmaceuticals | A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan |
| NCT01451411 | phase3 | terminated | 2012-02-01 | 2014-01-01 | Cumberland Pharmaceuticals | A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia |
| NCT00492037 | phase3 | completed | 2000-01-01 | — | Cumberland Pharmaceuticals | Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia |
| NCT00380575 | phase3 | completed | 2000-08-01 | — | Cumberland Pharmaceuticals | Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia |
| NCT00887627 | phase1 | completed | 2009-04-01 | 2010-07-01 | Cumberland Pharmaceuticals | Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 022016 | NDA | CUMBERLAND PHARMS |
Marketed products (1)
- VAPRISOL